Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
5-year follow-up of phase 1/2 BRUIN trial shows pirtobrutinib is active in relapsed or refractory Waldenström w/ ORR of 82.5% (but only 1 CR (1.3%)), 81% if had prior BTKi; neutropenia and anemia were most common ≥G3 AEs.”
Title: Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
Authors: M Lia Palomba, Manish R Patel, Toby A Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo Ma, Jonathon B Cohen, Krish Patel, Jennifer R Brown, Lydia Scarfò, Talha Munir, Ewa Lech-Maranda, Marc S Hoffmann, Chaitra S Ujjani, Bita Fakhri, Michael L Wang, Koji Izutsu, Hirokazu Nagai, Constantine S Tam, Joanna M Rhodes, Julie Vose, Matthew McKinney, James N Gerson, Minal A Barve, Bryone Kuss, Youngil Koh, Aisling Barrett, Steven P Treon, Jorge J Castillo, John F Seymour, Amy S Ruppert, Samuel C McNeely, Richard A Walgren, Donald E Tsai, Katherine Bao, Binoj Nair, Jennifer Woyach, Chan Y Cheah
You can read the Full Article in The Lancet Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
